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CASE STUDY
Production of thyrotropin receptor 
antibodies in acute phase of infectious 
mononucleosis due to Epstein–Barr virus 
primary infection: a case report of a child
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Jun‑ichi Ueyama2, Michiko Matsushita1, Satoshi Kuwamoto1, Masako Kato1, Ichiro Murakami1, Susumu Kanzaki2 
and Kazuhiko Hayashi1
Abstract 
Various autoantibodies have been reported to be detected during the progression of infectious mononucleosis. We 
observed a case of infectious mononucleosis due to Epstein–Barr virus primary infection for 2 months, and noticed 
the transiently increased titer of thyrotropin receptor autoantibodies detected at the acute phase on the 3rd day 
after admission. At that time, real‑time quantitative PCR also revealed the mRNA expressions of an immediate early 
lytic gene, BZLF1, and a latent gene, EBNA2. The expression of BZLF1 mRNA means that Epstein–Barr virus infects lyti‑
cally, and EBNA2 protein has an important role in antibody production as well as the establishment of Epstein–Barr 
virus latency. These results suggest that Epstein–Barr virus lytic infection is relevant to thyrotropin receptor autoanti‑
body production. Thyrotropin receptor autoantibodies stimulate thyroid follicular cells to produce excessive thyroid 
hormones and cause Graves’ disease. Recently, we reported the thyrotropin receptor autoantibody production from 
thyrotropin receptor autoantibody‑predisposed Epstein–Barr virus‑infected B cells by the induction of Epstein–Barr 
virus lytic infection in vitro. This case showed in vivo findings consistent with our previous reports, and is important to 
consider the pathophysiology of Graves’ disease and one of the mechanisms of autoimmunity.
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Background
Various autoantibodies have been reported to be 
detected in the serum, during the clinical course of infec-
tious mononucleosis (IM), which can be one of the fac-
tors explaining the relevance of Epstein–Barr virus (EBV) 
to autoimmune diseases (Sutton et al. 1974; Longnecker 
et al. 2013).
EBV is a common virus of Herpesviridae, and over 90 % 
of adults have its serum antibody. However, in developed 
countries, 50 % of children and young adults are seron-
egative and primary infection even in infants and young 
children is usually symptomatic or has nonspecific symp-
toms (Longnecker et al. 2013).
Since a report by Henle et  al. (1974), the serum lev-
els of EBV antibodies from onset to the convalescent or 
chronic phase have been well investigated (Longnecker 
et al. 2013; Henle et al. 1974; Cohen 2006; Luzuriaga and 
Sullivan 2010). Recently, real-time PCR for EBV viral 
load has become available, as well as serum titers of EBV 
antibodies for diagnosis. However, there are few reports 
monitoring the expression of EBV latent gene mRNA and 
lytic gene mRNA. We have been studying EBV reactiva-
tion (lytic infection) and autoimmune hyperthyroidism, 
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and reported that EBV lytic infection induction in vitro 
causes the production of thyrotropin (TSH) receptor 
antibodies (TRAbs) from host TRAb-predisposed EBV-
infected (TRAb(+)EBV(+)) B cells (Nagata et  al. 2014, 
2015).
We diagnosed this case of IM, as an EBV primary infec-
tion and followed it up for 2 months. Blood sampling was 
performed three times, once in the acute phase and the 
others in the convalescent phase. Investigation of these 
samples revealed that mRNA of an immediate early lytic 
gene, BZLF1, and of a latent gene, EBNA2, was expressed 
in the acute phase, and that heterogeneous autoantibod-
ies against TSH receptor, TRAbs, were also detected in 
the same acute lytic phase.
This case is important for considering the mecha-
nisms of autoantibody production induced by EBV lytic 
infection.
Case description
A boy who was 3  years and 10  months old was admit-
ted to our hospital on July 23. He had fever, appetite loss, 
and bilateral cervical lymph node enlargement with pain 
from July 21. We noticed that the tonsils were swollen 
with white exudates, the infra-auricular lymph nodes 
(right 5 × 2 cm, left 4 × 2 cm) were swollen and painful, 
and several neck lymph nodes (1 cm) were palpable. Nei-
ther axillar nor inguinal lymph nodes were swollen. The 
abdominal region was soft and flat, and hepato-spleno-
megaly was not apparent.
Laboratory data are shown in Table  1 and Fig.  1. 
C-reactive protein (CRP) increased to 3.63 mg/dl on the 
day of admission, but granulocytes were not increased. 
Lymphocytes increased to 50  %, with 9  % atypical lym-
phocytes. The patient was anemic and had slight liver 
dysfunction. Negative cytomegalovirus (CMV)-IgM and 
high titer of CMV-IgG indicated past infection of CMV, 
and positive EBV VCA-IgM was consistent with IM due 
to EBV primary infection.
Except for antibiotics against Moraxella Catarrhalis 
4+ and Haemophilus Influenzae 3+ detected from throat 
swab culture, rest alone was effective for recovery and the 
patient left hospital on the 5th day. He was observed for 
2 months as an outpatient.
From the blood samples, one taken in the acute phase 
and two in convalescent phase, we measured serum titers 
of EBV-VCA, -EBNA, -EA-D, and total immunoglobu-
lin by ELISA and EBV copy numbers by real-time PCR 
(Kimura et al. 1999).
In the examination on the 36th day, the condition of the 
patient was good, and the serum data indicated that he 
was already in the convalescent phase, with a decrease of 
VCA-IgM and an increase of VCA-IgG. EBV copy num-
ber was still high, but it usually remains high for 6 weeks 
after onset, so we considered that this would be reason-
able given the development of immunity in this child 
(Longnecker et  al. 2013). Through the follow-up, total 
immunoglobulin changed almost in parallel with VCA 
antibodies.
We examined serum autoantibodies of the 3 stored 
samples (at day 3, 36, and 64): anti-nuclear antibody 
(ANA) and anti-smooth muscle antibody (SMA), using 
fluorescent antibody (FA), and TRAbs by radio-receptor 
assay, at the same time for each antibody (Table 2). TRAb 
radio-receptor assay (DYNOtest TRAb Human; Yamasa 
Corporation, Choshi, Japan) were performed according 
to manufacturer’s instruction (clinical cut-off is 1 IU/l).
We constructed primers and probes for EBV latent 
genes and lytic genes (Table 3); then, we performed real-
time quantitative PCR to detect the mRNA expression of 
EBV latent genes and lytic genes (Table 2) (Kubota et al. 
2008; Ryan et al. 2004). The results indicated that mRNA 
of an immediate early lytic gene, BZLF1, and a latent 
gene, EBNA2, was detected in the acute phase, and that 
TRAbs were also detected in the same acute phase.
As a complication, this case had coagulopathy due to 
deficit of von Willebrand factor, but this disease is not 
accompanied by immune disorder and rarely has an 
effect on viral infection.
Discussion and evaluation
In EBV primary infection, most B cells become latently 
infected lymphoblastoid cells, and some B cells become 
Table 1 Laboratory data
July 23 July 25 August 27 September 24
Admission 3rd day 36th day 64th day
RBC (/μl) 3.86 × 106 3.71 × 106 4.24 × 106 4.18 × 106
Hgb (g/dl) 10.9 10.7 11.6 11.3
Platelet (/μl) 220 × 103 231 × 103 259 × 103 239 × 103
WBC (/μl) 9800 12,400 4600 5600
 Segmented (%) 32 15 41 38
 Band (%) 0 2 0 0
 Lymphocytes  
(%)
50 64 54 57
 Monocytes 9 8 3 2
 Atypical lym‑
phocytes (%)
9 11 1 0




AST (IU/l) 35 36 32 31
ALT (IU/l) 23 24 20 19
LDH (IU/l) 537 567 260 268
CRP (mg/dl) 3.63 2.2 0.02 0.02
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lytic infected cells (Longnecker et  al. 2013; Cohen 
2000). The lymphocytes of this case expressed mRNA 
of BZLF1, the immediate early gene of EBV lytic infec-
tion, and mRNA of EBNA2, the latent gene, in the acute 
phase (Table 2; Fig. 1). The expression of BZLF1 mRNA 
indicates that EBV lytic infection occurred in the acute 
phase of IM. EBNA2 is important for B cell transforma-
tion when EBV establishes its latent infection and is the 
transactivator of various genes, including LMP1 that acti-
vates NF-κB (Longnecker et  al. 2013); thus, it is related 
to antibody production and the expression of activation-
induced cytidine deaminase (Tran et al. 2010).
During IM, mRNA for latent genes as well as lytic 
genes could be expressed, but in this case, we could not 
detect mRNA other than BZLF1 and EBNA2. This might 
be related to the probably low potential of the immune 
system of this case of 3-year-old child to react to the 
invasion of viruses (Longnecker et al. 2013; Piątosa et al. 
2010; Parham 2009). Children at this age are also known 
to have weak antibody production (Longnecker et  al. 
2013; Parham 2009). In this case, we could not detect 
EA-D serum antibody and EA-D mRNA.
The levels of EBV VCA-IgM and serum total IgM were 
high in the acute phase and those of EBV VCA-IgG and 
serum total IgG rose in the convalescent phase (Table 2). 
These results imply that IgM production may be caused 
by EBV acute infection (Nakamura et  al. 1988; Casali 
et al. 1990).
Sutton et al. (1974) showed that SMA was detected at 
the onset of IM and declined in the convalescent phase, 
and that ANA and rheumatoid factor (RF) are rarely 
present and do not preferentially appear in the acute 
phase (Sutton et al. 1974; Longnecker et al. 2013). These 
increases of antibody production are considered to be the 
result of polyclonal B-cell activation in IM (Longnecker 
et al. 2013).
In our case, ANA and SMA were negative through-
out the observation period, but we could detect TRAbs 
at a low titer (Table  2). FA tests for ANA and SMA 



































BZLF1 mRNA (70.09 copies/µgDNA) and 
TRAbs (0.24 IU/L) were detected
(admission) (3rd day) (36th day) (64th day)
acute phase convalescent phase
Fig. 1 Time‑course change in this case. According to the decrease of 
inflammation represented by CRP, the number of atypical lympho‑
cytes decreased. The copy number of EBV began to decline in the 
convalescent phase. In the acute phase, EBV VCA‑IgM was higher 
than EBV VCA‑IgG, but in the convalescent phase, EBV VCA‑IgG was 
higher. BZLF1 mRNA (70.09 copies/μgDNA) and TRAbs (0.24 IU/l) were 
detected in the acute phase. *Index stands for sample absorbance/
absorbance of cut‑off serum. EBV Epstein–Barr virus, VCA viral capsid 
antigen, BZLF1 one of the EBV‑immediate‑early lytic genes, TRAb 
thyrotropin receptor antibody
Table 2 EBV copy numbers, serum antibodies, and expres-
sion of EBV mRNA
Each value of mRNA is normalized to the expression of β-actin
We used EBV mRNA from B95-8 strain as a reference
EBV Epstein–Barr virus, EA early antigen, EBNA, Epstein–Barr nuclear antigen, VCA 
viral capsid antigen, LMP latent membrane protein, TRAbs thyrotropin receptor 
antibodies, SMA smooth muscle antibody, ANA antinuclear antibody
* Index stands for sample absorbance/absorbance of cut-off serum
July 25 August 27 September 24
3rd day 36th day 64th day
EBV copy number (/106 WBC) 4.1 × 103 4.2 × 103 2.6 × 103
EBV‑EA‑IgG (index*) 0.4 (−) 0.3 (−) 0.3 (−)
EBV‑EBNA‑IgG (index*) 0.1 (−) 0.2 (−) 1.9 (+)
EBV‑VCA‑IgM (index*) 1.5 (+) 0.6 (±) 1.4 (+)
EBV‑VCA‑IgG (index*) 1.1 (+) 6.6 (+) 8.9 (+)
Total‑IgG (mg/ml) 11.15 13.37 9.49
Total‑IgM (μg/ml) 836.2 815.05 825.1
Autoantibodies
 ANA (x) (−) (−) (−)
 SMA (x) (−) (−) (−)
 TRAbs (IU/l) 0.24 (−) (−)
EBV mRNAs (copies/μgDNA)
 LMP1 (−) (−) (−)
 LMP2 (−) (−) (−)
 EBNA1 (−) (−) (−)
 EBNA2 4.29 (−) (−)
 BZLF1 70.09 (−) (−)
 EA‑D (−) (−) (−)
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radio-receptor assay. Using a more sensitive ELISA sys-
tem for ANA and SMA, a certain amount of antibodies 
might be detected, despite a low titer.
Several viral infections are recognized to induce 
autoantibody production, but the antibodies are often 
low level, and do not develop any clinical symptoms 
(Mandel et  al. 2011; Poole et  al. 2011; Camarero et  al. 
2008). Our case is too young to produce sufficient anti-
bodies, and did not show any specific autoimmune 
symptoms.
However, there are some cases reported to have devel-
oped Graves’ disease related to IM (Akahori et al. 2010), 
and this child needs long-term follow-up.
We observed that EBV lytic infection and autoantibody 
production occurred in the same period, which sug-
gests that EBV lytic infection stimulates autoantibody 
production.
EBV is a latent virus and persists mainly in B lympho-
cytes. B cells differentiate into antibody-producing cells; 
thus, persistent EBV may stimulate the antibody pro-
duction of host cells (Nagata et al. 2011, 2014, 2015). We 
have been investigating TRAb-production in Graves’ 
disease induced by EBV reactivation (lytic infection) 
(Nagata et  al. 2011, 2014, 2015). Our hypothesis is that 
lytic change of EBV in TRAb-predisposed and EBV-
infected (TRAb(+)EBV(+)) cells would stimulate host B 
cells to promote TRAb production with different level of 
efficiency between patients and controls, and may cause 
the development or exacerbation of Graves’ disease. We 
showed that TRAb(+)EBV(+) cells really exist in the 
peripheral blood of Graves’ disease patients and healthy 
controls (Nagata et  al. 2014), and these cells released 
TRAbs in culture fluid when we induced lytic change in 
persistent EBV (Nagata et al. 2015).
In EBV primary infection, some B cells become lytic 
(Longnecker et al. 2013; Cohen 2000). According to our 
hypothesis, these lytic infected B cells with TRAb pre-
disposition, differentiate to plasma cells and produce 
TRAbs. The result of research of this case in which 
EBV lytic gene expression and autoantibody production 
occurred simultaneously in the acute phase is consistent 
with our previous data in vitro and provides a suggestive 
example in vivo.
Conclusions
We have reported a 3-year-old patient with IM due to 
EBV primary infection. This case simultaneously showed 
EBV lytic gene expression and autoantibody (TRAb) pro-
duction in the acute phase of the disease.
This case is important to consider the pathophysiology 
of Graves’ disease and the mechanisms of autoantibody 
production induced by EBV lytic infection.
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 Sense 5′‑CCC TTT GTA TAC TCC TAC TGA TGA 
TCA C
Kubota et al. (2008)
 Anti‑
sense
5′‑ACC CGA AGA TGA ACA GCA CAA T Kubota et al. (2008)
 Probe 5′‑CTC ATC GCT CTC TGG AAT TTG CAC 
GG
Kubota et al. (2008)
LMP2
 Sense 5′‑AGC TGT AAC TGT GGT TTC CAT GAC
 Anti‑
sense
5′‑GCC CCC TGG CGA AGA G
 Probe 5′‑CTG CTG CTA CTG GCT TTC GTC CTC 
TGG
EBNA1
 Sense 5′‑TAC AGG ACC TGG AAA TGG CC Ryan et al. (2004)
 Anti‑
sense
5′‑TCT TTG AGG TCC ACT GCC G Ryan et al. (2004)
 Probe 5′‑AGG GAG ACA CAT CTG GAC CAG 
AAG GC
EBNA2
 Sense 5′‑TCT TGC GTT ACA TGG GGG AC
 Anti‑
sense
5′‑CCT GGT AGG GAT TCG AGG GA
 Probe 5′‑AAT TGT TGA CAC GGA TAG TCT TGG
BZLF1
 Sense 5′‑AAA TTT AAG AGA TCC TCG TGT AAA 
ACA TC
Ryan et al. (2004)
 Anti‑
sense
5′‑CGC CTC CTG TTG AAG CAG AT Ryan et al. (2004)
 Probe 5′‑ATA ATG GAG TCA ACA TCC AGG CTT 
GGG C
EA‑D
 Sense 5′‑CGT GCC AAT CTT GAG GTT TT
 Anti‑
sense
5′‑CAC CCG GGG ACT TTT ATC TT
 Probe 5′‑TTT ATT TAA CCA CGC CTC CG
β‑Actin
 Sense 5′‑CCT GGC ACC CAG CAC AAT G
 Anti‑
sense
5′‑GCC GAT CCA CAC GGA GTA CT
 Probe 5′‑ATC AAG ATC ATT GCT CCT CCT GAG 
CGC
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